ArticleThe Journal of veterinary medical science2017
In vitro synergistic activities of cefazolin and nisin A against mastitis pathogens.
Article in The Journal of veterinary medical science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Probiotic-Derived Bacteriocins for Veterinary Biofilm Control: Mechanisms, Evidence, and One Health Translation.Probiotics and antimicrobial proteins · 2026Review
- Bacteriocins as a Promising Antimicrobial Strategy Against Multidrug-Resistant Pathogens: Mechanisms of Action, Applications in Human and Animal Health, and the Food Industry.BioMed research international · 2026Review
- In Vitro Activity of Nisin A Against Staphylococci Isolated from Periprosthetic Joint Infection.Antibiotics (Basel, Switzerland) · 2025Article
- From Herd Health to Public Health: Digital Tools for Combating Antibiotic Resistance in Dairy Farms.Antibiotics (Basel, Switzerland) · 2024Review
- Pharmacological composition based on bacteriocinnisin in experimentsOpen veterinary journal · 2024Article
- Effect of nisin and p-coumaric acid on autoinducer-2 activity, biofilm formation, and sprE expression of Enterococcus faecalis.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Prevalence and Characterization ofInfection and drug resistance · 2023Article
- Bioengineered Nisin A Derivatives Display Enhanced Activity against Clinical Neonatal Pathogens.Antibiotics (Basel, Switzerland) · 2022Article
- Bacterial Cellulose Membranes as Carriers for Nisin: Incorporation, Antimicrobial Activity, Cytotoxicity and Morphology.Polymers · 2022Article
- Efficacy of antimicrobial therapy for bovine acute Klebsiella pneumoniae mastitis.The Journal of veterinary medical science · 2022Article
- Susceptibility to Nisin, Bactofencin, Pediocin and Reuterin of Multidrug ResistantAntibiotics (Basel, Switzerland) · 2021Article
- A Bioengineered Nisin Derivative To Control Streptococcus uberis Biofilms.Applied and environmental microbiology · 2021Article
- Plantaricin NC8 αβ prevents Staphylococcus aureus-mediated cytotoxicity and inflammatory responses of human keratinocytes.Scientific reports · 2021Article
- Gram-positive bacteriocins: usage as antimicrobial agents in veterinary medicine.Veterinary research communications · 2020Review
- Broadening and Enhancing Bacteriocins Activities by Association with Bioactive Substances.International journal of environmental research and public health · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
First-generation cephalosporins such as cefazolin (CEZ) have been widely used for mastitis treatment in dairy cattle. However, the use of antibiotics results in the presence of antibiotic residues in milk, which is used for human consumption. Nisin A, a bacteriocin produced by Lactococcus lactis, has been used as a broad-spectrum food preservative for over 50 years. Therefore, a combination of CEZ and nisin A might provide an extended activity spectrum against mastitis pathogens and reduce the antibiotic dose for mastitis treatment. This study aimed to evaluate the combined effect of CEZ and nisin A against mastitis pathogens using the checkerboard and time-kill assays. In the checkerboard assay, the CEZ-nisin A combination exhibited a synergistic effect against Staphylococcus aureus (n=20/20) and Enterococcus faecalis (n=13/18), and meanwhile exhibited a mostly additive effect against Staphylococcus intermedius (n=12/20), Streptococcus agalactiae (n=10/10), Streptococcus dysgalactiae (n=18/18), and Escherichia coli (n=14/18). There were no indifferent or antagonistic effects between CEZ and nisin A. In the time-kill assay, the CEZ-nisin A combination at 0.5 × or 1 × minimum inhibitory concentration exhibited synergistic reduction of bacterial growth by over 3 log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.